Management Team

For the past two decades, Paul has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals and Gilead.

He has also provided financial leadership and business development for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales. Throughout his tenure, he structured and closed major transactions that brought high-value products to the Japanese pharmaceutical market. Additionally, his other corporate responsibilities included overall evaluation of corporate asset values for purposes of divestiture or acquisition. Paul subsequently cofounded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., that is now one of Japan’s most successful orphan drug companies. As President of the U.S. division and a cofounder, he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.

As an adult-onset Type 1 diabetic, he knows firsthand how a patient can struggle to get the right diagnosis and treatment. Only 40,000 adults a year are diagnosed with Type 1 diabetes. Paul is actively involved in the Juvenile Diabetes Research Foundation (JDRF), an organization funding research for Type 1 diabetes.

I Richard Garr, J.D., was a Director, and Neuralstem’s Chief Executive Officer and President from 1996 through February of 2016. Additionally, as a co-founder and General Counsel at Neuralstem, Mr. Garr had responsibility and oversight for all operations of a world-leading regenerative medicine company developing cell and gene therapies, small molecule drugs and genomic database products. He was responsible for worldwide business development, joint ventures, and licensing, a worldwide intellectual property portfolio and among other firsts created the stem cell industry’s first development agreements for Korea, Indonesia, Singapore, Malaysia, and Vietnam.

In 2016, Mr. Garr became a full-time advocate for patient’s rights to access experimental treatments in development both in the U.S. and Europe. In 2018, he founded Access Hope CRO, the only CRO dedicated exclusively to facilitating safe, ethical, and legal expanded patient access to potentially life-saving investigational treatments under the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2018. Mr. Garr is a graduate of Drew University (1976) and the Columbus School of Law, The Catholic University of America (1979).

Additionally, he was a founder and is a current Board member of the First Star Institute, a children’s charity focused on abused children’s issues; a founder of The Starlight Foundation Mid-Atlantic chapter, which focuses on helping seriously ill children; and a past Honorary Chairman of the Brain Tumor Society.

Ronald Bordens is an accomplished executive scientist with over 40 years of successful experience in biotechnology and pharmaceutical industries for companies focused on research and development.

He possesses a unique skill set including but not limited to people leadership, scientific expertise, and quality assurance and control. His pharmaceutical industry experience includes drug discovery, drug development and research technology with a focus on bioanalytical research, biomarkers, and leadership development during his 26-year career at Schering-Plough Research.